Printed From BioPortfolio.com
FDA Grants Tentative Approval to Eagle Pharmaceuticals’ Pemfexy (Pemetrexed Injection) Ready-to-Dilute
10:13 EDT 30 Oct 2017 | Speciality Pharma Journal
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) today announced that the United States Food and Drug Administration (“FDA”) has granted tentative approval for the Company’s PEMFEXY™, a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small …
Original Article: FDA Grants Tentative Approval to Eagle Pharmaceuticals’ Pemfexy (Pemetrexed Injection) Ready-to-Dilute
